Nantahala Discloses 9.99% Stake in Quince Therapeutics (QNCX)
Quince Therapeutics, Inc. Schedule 13G filed by Nantahala Capital Management, LLC and two individuals reports collective beneficial ownership of 4,765,862 shares, representing 9.99% of outstanding common stock as of June 30, 2025.
Rhea-AI Filing Summary
Quince Therapeutics, Inc. Schedule 13G filed by Nantahala Capital Management, LLC and two individuals reports collective beneficial ownership of 4,765,862 shares, representing 9.99% of outstanding common stock as of June 30, 2025. The reported holdings include 2,237,562 shares that the reporting persons may acquire within 60 days through the exercise of warrants. Nantahala and principals Wilmot B. Harkey and Daniel Mack report no sole voting or dispositive power but share voting and dispositive power over all reported shares. Blackwell Partners LLC - Series A, a fund advised by Nantahala, is identified as having rights to dividends or sale proceeds on more than 5% of the shares reported.
Positive
- None.
Negative
- None.
Insights
TL;DR: Nantahala reports a near-10% stake in QNCX, including warrants exercisable within 60 days, with shared voting/control but no sole voting power.
The filing discloses that Nantahala, an investment adviser, and its managing members each may be deemed beneficial owners of 4,765,862 shares, or 9.99% of Quince Therapeutics. The inclusion of 2,237,562 warrant-acquirable shares is material to calculating potential dilution and control thresholds. The reporting persons state shared voting and dispositive power only, indicating collective rather than unilateral control. The identification of Blackwell Partners LLC - Series A as a holder with dividend/sale proceeds rights clarifies that some voting influence arises through advised fund relationships. This is a routine 13G disclosure under passive/investment-adviser classification.
TL;DR: Filing shows significant passive stake with shared authority; no indication of an intent to change control.
The Schedule 13G classification and the certification language state the securities are held in the ordinary course of business and not to influence control, consistent with an investment adviser filing. Shared voting and dispositive power across Nantahala and its principals implies governance influence is exercised collectively through the adviser structure rather than by an individual. The presence of exercisable warrants increases the effective economic exposure but the filing does not assert any plans to act as a control group. For investors, the disclosure clarifies ownership concentration near a 10% threshold.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What stake does Nantahala report in Quince Therapeutics (QNCX)?
Is the filing made as a passive investor or with intent to influence control?
Which fund advised by Nantahala is identified in the filing?
AI-generated analysis. How Rhea-AI works. Not financial advice.